Core Viewpoint - The acquisition of Optimed by Guichuang Tongqiao marks a significant milestone in the company's globalization strategy, enhancing its market presence in Europe and globally while leveraging synergies between its production bases in China and Germany [1][2]. Group 1: Acquisition Details - Guichuang Tongqiao has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH in a phased manner, with options for future acquisition of remaining shares [1]. - The acquisition aims to utilize Optimed's established R&D, manufacturing, and commercialization platform in Europe to accelerate the promotion and implementation of innovative products in international markets [1]. Group 2: Optimed Overview - Optimed is a German medical technology company focused on the development, production, and global sales of minimally invasive vascular and urological intervention medical devices [2]. - The company has a sales and service network covering over 70 countries and maintains close collaborations with European clinicians and academic opinion leaders [2]. - Optimed's peripheral venous treatment products, including the sinus-Venous iliac vein stent, have gained significant market recognition and have been validated in clinical trials such as STEVECO [2].
归创通桥盘中涨近5% 近日战略收购德国Optimed 将进一步拓展血管介入全球市场布局